TRIPEPI, GIOVANNI LUIGI
 Distribuzione geografica
Continente #
NA - Nord America 158
EU - Europa 134
AS - Asia 80
Totale 372
Nazione #
US - Stati Uniti d'America 157
IT - Italia 103
CN - Cina 47
SG - Singapore 31
FI - Finlandia 11
DE - Germania 9
AT - Austria 4
RU - Federazione Russa 3
CZ - Repubblica Ceca 2
NL - Olanda 2
AE - Emirati Arabi Uniti 1
KR - Corea 1
PA - Panama 1
Totale 372
Città #
Florence 74
Boardman 43
Ashburn 27
Singapore 25
Shanghai 16
Noto 11
Sesto Fiorentino 11
Helsinki 10
Washington 10
Los Angeles 7
Munich 4
Beijing 3
Vienna 3
Amsterdam 2
Falkenstein 2
Jinhua 2
New York 2
Ogden 2
Wuhan 2
Cirò Marina 1
Dubai 1
Guangzhou 1
Lappeenranta 1
Milan 1
Ningbo 1
Nuremberg 1
San Francisco 1
Santa Clara 1
Seoul 1
Tiantai Chengguanzhen 1
Udine 1
Wuxi 1
Zhengzhou 1
Totale 270
Nome #
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 37
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 37
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 32
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 31
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 31
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 30
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 28
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 27
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 26
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 26
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 25
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 24
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 16
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 12
Long-term cognitive function changes with non-vitamin K oral anticoagulants in older patients with atrial fibrillation. A multicenter cohort study 6
Totale 388
Categoria #
all - tutte 3.564
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.564


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202328 0 0 0 0 0 0 14 0 0 3 11 0
2023/2024239 3 8 52 46 29 32 14 4 4 2 4 41
2024/2025121 9 32 8 25 24 23 0 0 0 0 0 0
Totale 388